Treatment of Multiple Myeloma: Best Practices from The MD Anderson Cancer Center and Satellites

Expert panelists review available induction therapy regimens for patients newly diagnosed with transplant-eligible multiple myeloma in the context of clinical data.

A brief overview of stem cell transplant’s role in the first-line treatment setting of newly diagnosed multiple myeloma.

Shared insight on the respective value of consolidation therapy and collaborative tumor boards when managing patients with transplant-eligible multiple myeloma.

Centering discussion on transplant ineligible multiple myeloma, expert panelists review mainstay treatment regimens and strategies in the first-line setting.

Key opinion leaders in multiple myeloma consider duration of therapy and the possibility of treatment discontinuation for newly diagnosed patients.

Switching focus to the relapsed/refractory setting, panelists reflect on the treatment armamentarium available to patients with multiple myeloma at early relapse.

A brief conversation on the introduction and use of bispecifics and CAR T-cell therapies in satellite campuses for patients with relapsed/refractory multiple myeloma.

Key opinion leaders share comprehensive insight on optimal dosing and sequencing strategies in patients with relapsed/refractory multiple myeloma.

Focused discussion on mitigating and managing the adverse event profiles of bispecifics in relapsed/refractory multiple myeloma.

Experts in multiple myeloma management review the role of CAR T-cell therapy in patients with relapsed/refractory disease.

Closing out their discussion on multiple myeloma, expert panelists share expectations and hopes for the future treatment paradigm.

Ashley E. Rosko, MD, recaps a recent panel discussion on treatment options for multiple myeloma, and discusses the disease space more generally.